BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials
on January 15, 2018
Bio Analytical Research Corporation (BARC), the global central laboratory division of Cerba HealthCare, today announces that Biogazelle will join the pool of expert laboratories they consistently collaborate with.
BARC is a harmonized network of clinical laboratories present on five continents. For the past several years, BARC has regularly expanded its collaborations with expert clinical R&D partners. This ongoing expansion allows BARC and its customers an easy access to state-of-the-art technologies and expert advice, ranging from solid tissue work to flow cytometry or genetics in this case.
Mario PAPILLON, BARC’s CEO said: “While Next-Generation Sequencing of DNA has already revolutionized the way we can stratify and treat patients, working on circulating DNA and RNA is a new frontier that our sponsors are keen on exploring. With a recognized expertise in the detection of microRNAs, long non-coding RNAs and mRNA biomarker signatures, as well as in digital PCR, Biogazelle is the type of partner that will allow our customers access to new key patient biological information. As such, BARC is really proud being able to add these services in a transparent and seamless way.”
As PCR and RNA sequencing service provider, Biogazelle’s ambition is to deliver consistent quality and technically valid results. Therefore, Biogazelle has established a quality management system based on the international standard ISO/IEC 17025:2005. More recently, Biogazelle has extended its quality management system to create a GCLP (Good Clinical Laboratory Practices) compliant environment for its service activities, thus supporting its customers with genetic testing in clinical trials.
“For Biogazelle, scientific quality and integrity are extremely important. Therefore, we want to guarantee the quality of the work we do as a PCR and RNA sequencing service provider.” said Jan HELLEMANS, Biogazelle’s CEO. “Through the collaboration with BARC, we can now offer our truly unique workflows in the field of RNA and DNA to sponsors aiming at incorporating innovative analyses in their clinical trials, bringing the latest technologic advancements to the clinic.”
About BARC: For over 3 decades, BARC Global Central Lab has provided the pharmaceutical and biotech industry with central lab services both in routine and specialized testing within a wide range of fields including oncology, immunology, genetics, microbiology and clinical pathology. BARC’s laboratories routinely conduct medical clinical testing, thus ensuring that the tests offered are also performed on a daily basis for diagnostic purposes, patient stratification, staging and follow-up. With cutting-edge technologies at their disposal, BARC’s medical and scientific experts are specialists in their fields equipped for delivering more than just testing. At BARC, they act as genuine partners for our customers. We encourage that our science Liaisons are integrated in our customer’s R&D processes, hence providing a critical advantage in the ever increasing complex setting of clinical trials.
About Biogazelle: Biogazelle offers expert laboratory services in nucleic acid quantification (gene expression, mutation and copy number analysis) to support its customers in their development of diagnostics and therapeutics. Customized workflows for clinically relevant samples – from liquid biopsies to fixed tissues – are available. In addition, Biogazelle’s advanced RNA biomarker development program offers an end-to-end solution from RNA biomarker panel discovery (including liquid biopsies) to the development of a PCR-based molecular diagnostic test. Biogazelle also serves as a specialty lab in the field of clinical trials and in routine diagnostic settings.